Clarity in biologics discovery

Biologics discovery moves fast. Your data needs to keep pace.

Most biologics programs are shaped by a small set of early decisions made with incomplete or inconsistent data. Target biology, competitive activity, and safety risk data are distributed across literature, patents, and multiple specialized databases with limited standardization between them. By the time your team assembles a clear picture of a target, the landscape has shifted, and a competitor may already be ahead.

This white paper maps the three decisions that make or break a biologics program and shows how better-connected data changes each one.

• Target selection
  How do you evaluate novelty, biological relevance, and existing intellectual property when information is spread across publications and patents?

• Lead prioritization in low-precedent space
  When structure–activity relationships are limited or unavailable, what types of published and derived bioactivity data can help inform prioritization decisions?

• Early identification of safety risk
  What signals related to ADME and toxicology can be identified from available data, and how early can they inform target or program-level decisions?

Curated from thousands of life sciences journals, over 100 patent authorities, and trusted biological and pharmacological databases, this paper draws on the same data infrastructure that powers CAS BioFinder^®.

See how leading discovery teams are making faster, more defensible target decisions without weeks of manual literature review.